Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019

September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...

PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019

September 11, 2019 — The angiotensin...

Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019

September 9, 2019 — Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary...

Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019

September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF...

Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019

September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart...

Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients
News | Heart Failure | September 04, 2019

September 4, 2019 – Novartis announced results from two new...

Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019

August 27, 2019 — Imagine there were a drug that you could take soon after a...

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019

July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can...

Statins Reduce Stroke, Cardiovascular Risk in Cancer Patients Following Radiation
News | Cardio-oncology | July 29, 2019

July 29, 2019 — Cancer patients taking cholesterol-lowering...

Global Afib Patient Registry Shows New Tools Needed to Assess Patient Risk
News | Patient Engagement | June 17, 2019

June 17, 2019 – Initial results from the AVIATOR 2...

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019

June 14, 2019 — Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its...

Overlay Init